Vicriviroc maleate
Code | Size | Price |
---|
TAR-T3435-1mg | 1mg | £132.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T3435-5mg | 5mg | £209.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T3435-1mL | 1 mL * 10 mM (in DMSO) | £230.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T3435-10mg | 10mg | £295.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T3435-25mg | 25mg | £516.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T3435-50mg | 50mg | £711.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T3435-100mg | 100mg | £946.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Images
Documents
Further Information
Bioactivity:
Vicriviroc maleate(Sch-417690) is a piperazine-based CCR5 receptor antagonist with activity against human immunodeficiency virus. The IC50 value is 0.91 nM in clinical development for the treatment of HIV-1.
CAS:
599179-03-0
Formula:
C32H42F3N5O6
Molecular Weight:
649.712
Pathway:
Proteases/Proteasome; Immunology/Inflammation; Microbiology/Virology
Purity:
0.9751
SMILES:
OC(=O)C=C/C(O)=O.COC[C@H](N1CCN(C[C@@H]1C)C1(C)CCN(CC1)C(=O)c1c(C)ncnc1C)c1ccc(cc1)C(F)(F)F
Target:
HIV Protease; CCR
References
Malt?z, Fernandoa; Doroana, Manuelab; Branco, Teresac et al. Current Opinion in HIV & AIDS. 2011 ,6:S21-S30.
Edward O'Mara, Claudia Kasserra, John Robert Huddlestone,et al. Antimicrob Agents Chemother. 2010; 54(6): 2448-2454.
Sanjay Bhattacharya, Husam Osman. Novel targets for anti-retroviral therapy. Journal of Infection. 2009,59(6): 377-386.